|
|
News Breaks | | | | November 11, 2012 | | 12:50 EDT |  | IDIX | Idenix reports clinical data for HCV drug candidates - IDX719 and IDX184
Idenix Pharmaceuticals announced the presentation of safety and antiviral activity results for the company's clinical-stage hepatitis C virus, HCV, drug candidates – IDX719, a next-generation pan-genotypic NS5A inhibitor, and IDX184, a nucleotide polymerase inhibitor. Idenix presented updated clinical findings from a three-day proof-of-concept study, which demonstrated that IDX719 was well-tolerated at daily doses up to 100 mg and showed potent antiviral activity across HCV genotypes 1-4, with mean maximal viral load reductions up to approximately 4.0 log10 IU/mL. The company also presented updated cardiovascular safety and antiviral activity data from the phase IIb study of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV). The IDX719 and IDX184 clinical data are being reported in poster presentations during the 63rd Annual Meeting for the American Association for the Study of Liver Diseases, AASLD, in Boston. | |
|
News For IDIX From The Last 14 Days Check below for free stories on IDIX the last two weeks. |
|
|
| May 21, 2013 | | 07:34 EDT |  | IDIX | UBS to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
